About Tonix Pharmaceuticals (NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155
Debt
Debt-to-Equity RatioN/A
Current Ratio12.47%
Quick Ratio12.47%
Price-To-Earnings
Trailing P/E Ratio-1.10
Forward P/E Ratio-1.19
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-21,120,000.00
Net MarginsN/A
Return on Equity-74.46%
Return on Assets-69.58%
Miscellaneous
Employees14
Outstanding Shares7,830,000
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals (NASDAQ:TNXP) announced its quarterly earnings results on Monday, March, 12th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
4 brokerages have issued twelve-month target prices for Tonix Pharmaceuticals' shares. Their predictions range from $6.00 to $10.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $8.3333 in the next twelve months. View Analyst Ratings for Tonix Pharmaceuticals.
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include Immutep (IMMP), Novus Therapeutics (NVUS), Imprimis Pharmaceuticals (IMMY), AzurRx BioPharma (AZRX), Vivus (VVUS), IntelGenx Technologies (IGXT), Celsion (CLSN), Edge Therapeutics (EDGE), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), Lipocine (LPCN), Egalet (EGLT), Chiasma (CHMA), PLx Pharma (PLXP), OvaScience (OVAS), Pernix Therapeutics (PTX), Jaguar Health (JAGX) and Innovus Pharmaceuticals (INNV).
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman M.D., Co-Founder, Pres, CEO & Chairman (Age 60)
- Dr. Donald W. Landry, Co-Founder & Director (Age 63)
- Mr. Bradley Saenger CPA, CFO & Treasurer (Age 44)
- Dr. Gregory M. Sullivan M.D., Chief Medical Officer & Sec. (Age 52)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
Has Tonix Pharmaceuticals been receiving favorable news coverage?
Media stories about TNXP stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the company an impact score of 46.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $3.19.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $25.53 million. The company earns $-21,120,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVE SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tonix Pharmaceuticals (NASDAQ:TNXP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Tonix Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.3333, suggesting that the stock has a possible upside of 161.23%. The high price target for TNXP is $10.00 and the low price target for TNXP is $6.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.3333 | $8.3333 | $8.3333 | $8.3333 |
| Price Target Upside: | 161.23% upside | 117.01% upside | 117.01% upside | 159.61% upside |
Tonix Pharmaceuticals (NASDAQ:TNXP) Consensus Price Target History
Tonix Pharmaceuticals (NASDAQ:TNXP) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Tonix Pharmaceuticals (NASDAQ:TNXP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 15.36%
Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/26/2017 | Seth Lederman | CEO | Buy | 5,300 | $3.61 | $19,133.00 | 11,166 |  |
| 12/21/2017 | Ernest Mario | Director | Sell | 36,967 | $3.51 | $129,754.17 | 10,000 | |
| 12/18/2017 | Ernest Mario | Director | Sell | 10,000 | $3.57 | $35,700.00 | 10,000 | |
| 12/14/2017 | Ernest Mario | Director | Sell | 1,967 | $3.58 | $7,041.86 | 10,000 | |
| 8/17/2017 | Seth Lederman | CEO | Buy | 20,000 | $3.00 | $60,000.00 | 11,166 | |
| 6/30/2017 | Ernest Mario | Director | Sell | 6,105 | $4.28 | $26,129.40 | 63,073 | |
| 6/30/2017 | Seth Lederman | CEO | Buy | 5,000 | $4.33 | $21,650.00 | 7,912 | |
| 6/26/2017 | Seth Lederman | CEO | Buy | 5,000 | $4.40 | $22,000.00 | 7,912 | |
| 6/20/2017 | Seth Lederman | CEO | Buy | 20,000 | $4.22 | $84,400.00 | 7,912 | |
| 11/23/2016 | Ernest Mario | Director | Buy | 120,000 | $0.41 | $49,200.00 | 630,724 | |
| 9/13/2016 | Ernest Mario | Director | Buy | 100,000 | $0.79 | $79,000.00 | 530,724 | |
| 6/22/2016 | Seth Lederman | CEO | Buy | 20,000 | $2.08 | $41,600.00 | 80,815 | |
| 6/21/2016 | Bradley Saenger | CFO | Buy | 2,000 | $2.00 | $4,000.00 | 6,039 | |
| 6/21/2016 | Bruce Daugherty | Insider | Buy | 100,000 | $2.00 | $200,000.00 | 65,777 | |
| 6/21/2016 | John B Rhodes | Director | Buy | 25,000 | $2.00 | $50,000.00 | 112,196 | |
| 6/3/2016 | Gregory M Sullivan | Insider | Buy | 20,000 | $2.50 | $50,000.00 | 43,185 | |
| 5/12/2016 | Ernest Mario | Director | Buy | 31,042 | $2.30 | $71,396.60 | 380,724 | |
| 5/11/2016 | Ernest Mario | Director | Buy | 8,210 | $2.24 | $18,390.40 | 349,682 | |
| 3/23/2016 | Seth Lederman | CEO | Buy | 8,000 | $2.44 | $19,520.00 | 80,815 | |
| 3/16/2016 | Ernest Mario | Director | Buy | 75,000 | $2.29 | $171,750.00 | 341,472 | |
| 9/30/2015 | Gregory M Sullivan | Insider | Buy | 5,000 | $5.18 | $25,900.00 | 16,925 | |
| 9/28/2015 | Gregory M Sullivan | Insider | Buy | 4,694 | $5.95 | $27,929.30 | 11,925 | |
| 9/25/2015 | Seth Lederman | CEO | Buy | 6,000 | $6.50 | $39,000.00 | 71,074 | |
| 8/26/2015 | Ernest Mario | Director | Buy | 10,000 | $6.05 | $60,500.00 | 260,472 | |
| 8/25/2015 | Ernest Mario | Director | Buy | 1,468 | $6.40 | $9,395.20 | 250,472 | |
| 8/24/2015 | Ernest Mario | Director | Buy | 2,532 | $6.20 | $15,698.40 | 249,004 | |
| 8/20/2015 | Ernest Mario | Director | Buy | 6,000 | $6.64 | $39,840.00 | 246,472 | |
| 8/17/2015 | Ernest Mario | Director | Buy | 15,000 | $6.93 | $103,950.00 | | |
| 7/17/2015 | John B Rhodes | Director | Buy | 6,000 | $7.50 | $45,000.00 | | |
| 7/17/2015 | Leland Gershell | CFO | Buy | 1,000 | $7.50 | $7,500.00 | | |
| 6/11/2015 | Gregory M Sullivan | Insider | Buy | 4,500 | $8.38 | $37,710.00 | | |
| 3/17/2015 | Seth Lederman | CEO | Buy | 2,000 | $7.02 | $14,040.00 | | |
| 3/13/2015 | Seth Lederman | CEO | Buy | 2,000 | $7.24 | $14,480.00 | | |
| 3/11/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.95 | $13,900.00 | | |
| 3/10/2015 | Charles E Iv Mather | Director | Buy | 1,000 | $6.80 | $6,800.00 | | |
| 3/9/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.48 | $12,960.00 | | |
| 3/6/2015 | Ernest Mario | Director | Buy | 4,000 | $6.57 | $26,280.00 | | |
| 3/5/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.27 | $12,540.00 | | |
| 2/9/2015 | Ernest Mario | Director | Buy | 30,000 | $5.85 | $175,500.00 | | |
| 2/9/2015 | Leland Gershell | CFO | Buy | 5,000 | $5.85 | $29,250.00 | | |
| 9/27/2013 | Charles E Iv Mather | Director | Buy | 1,000 | $3.65 | $3,650.00 | | |
(Data available from 1/1/2013 forward)
Tonix Pharmaceuticals (NASDAQ TNXP) News Headlines
| Source: |
|
Tonix Pharmaceuticals (NASDAQ:TNXP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tonix Pharmaceuticals (NASDAQ:TNXP) Income Statement, Balance Sheet and Cash Flow Statement
Tonix Pharmaceuticals (NASDAQ TNXP) Stock Chart for Saturday, April, 21, 2018
Loading chart…
